Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer

Li, Yijin; Vennapusa, Bharathi; Chang, Ching‐Wei; Tran, David; Nakamura, Rin; Sumiyoshi, Teiko; Hegde, Priti S.; Molinero, Luciana

doi:10.1097/pai.0000000000000857

Cited by 29 publications

(35 citation statements)

References 27 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, subgroup analysis according to antibody used for PD-L1 assessment was only possible for SP142 clone. When analyzed regardless of cell of expression and IHC subtype, the pooled PD-L1 positivity rate according to SP142 was higher at the primary tumor (44.4%, 95% CI: 29.8-59.5, I 2 = 98.2%) than in metastatic tissue (28.4%, 95% CI: 17.8-40.2, I 2 = 80%; p < 0.001) [14,21,22,24,26,30,35,36].…”

Section: Pd-l1 Protein Expression In Primary Tumor and Metastasis In Subgroups Of Interestmentioning

confidence: 96%

“…1, while the detailed documentation of the search strategy is provided as Supplementary Data. Using this selection strategy, 20 studies were included in the metaanalysis [14,[21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. The study characteristics are presented in Table 1.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…prospective clinical trials. Out of the sixteen studies that had been published in full form, the median quality score according to REMARK was 26 (range, [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33].…”

Section: Quality Of Eligible Studies Between-study Heterogeneity and Publication Biasmentioning

confidence: 99%

“…When analyzing studies reporting on PD-L1 positivity rates according to the approved indication of atezolizumab in combination with nabpaclitaxel at the first line setting, i.e. TNBC and PD-L1 expression assessed on immune cells using clone SP142 [14,21,26,30,35], the pooled PD-L1 positivity rate was 55.2% (95% CI, 45.7-64.5; 5 studies, n = 1120) for primary tumor and 37.5% (95% CI, 33.8-41.3; 5 studies, n = 649) for metastasis, a statistically significant difference (p < 0.001). Substantial heterogeneity was noted on the analysis of primary tumor PD-L1 positivity rates (I 2 = 86.6%), but not on the analysis of metastatic lesions (I 2 = 8%).…”

Section: Pd-l1 Protein Expression In Primary Tumor and Metastasis In Subgroups Of Interestmentioning

confidence: 99%

See 3 more Smart Citations

Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

Boman

Zerdes

Mårtensson

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

Programmed cell death ligand 1 (PD-L1) expression is predictive for benefit from immunotherapy in several human malignancies including triple negative breast cancer. Lower positivity rates but a larger relative benefit from atezolizumab has been implied when PD-L1 status is assessed at metastatic sites. We aimed to study the discordance of PD-L1 expression between primary tumor and metastasis in breast cancer due to its potential clinical utility. Methods: Cochrane Library, Embase, Medline and Web of science were searched for studies reporting on PD-L1 expression in primary and metastatic breast cancer, followed by data extraction. Outcomes included pooled PD-L1 positivity rates in tumor cells, immune cells or both in primary tumor and metastasis, PD-L1 discordance between matched primary tumors and metastasis and direction of discordance. Results: Of 2552 identified entries following de-duplication, 20 studies fulfilled the predefined inclusion criteria. Pooled PD-L1 positivity rate was higher in primary tumors compared to metastasis when assessed in immune cells (51.2% vs 37.1% p < 0.001) and tumor/immune cells (30.1% vs 14.6% p < 0.001), but not in tumor cells (18.7% vs 17.8% p = 0.65). PD-L1 positivity was lowest when assessed in bone metastases (12%) and highest in lymph nodes (60%). Discordance between primary tumors and metastasis was bidirectional, with higher pooled discordance rates when PD-L1 expression was assessed in immune compared to tumor cells (39.5% vs 13.6%, p < 0.001). Conclusion:The observed considerable discordance between PD-L1 status in primary and metastatic breast cancer emphasizes the importance of appropriate tissue sampling when selecting patients for immunotherapy.

show abstract

Section: Pd-l1 Protein Expression In Primary Tumor and Metastasis In Subgroups Of Interestmentioning

confidence: 96%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Quality Of Eligible Studies Between-study Heterogeneity and Publication Biasmentioning

confidence: 99%

Section: Pd-l1 Protein Expression In Primary Tumor and Metastasis In Subgroups Of Interestmentioning

confidence: 99%

See 2 more Smart Citations

Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

Boman

Zerdes

Mårtensson

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…The percentage of TILs was lower in metastasis compared with PBC, especially TNBC showed the most decrease (5% in BCBM, 20% in PBC; p = 0.022) [ 124 ]. Li et al reported a higher prevalence of PD-L1 expression on immune cells in the brain compared to the liver and bone (50.0% in the brain, 26.9% in the liver, and 25.0% in bone) [ 125 ], however, the number of patients with BMs is limited to four and it is not a definitive.…”

Section: Systemic Therapy For Bcbmmentioning

confidence: 99%

Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives

Watase

Shiino

Shimoi³

et al. 2021

Cancers

View full text Add to dashboard Cite

Breast cancer is the second most common origin of brain metastasis after lung cancer. Brain metastasis in breast cancer is commonly found in patients with advanced course disease and has a poor prognosis because the blood–brain barrier is thought to be a major obstacle to the delivery of many drugs in the central nervous system. Therefore, local treatments including surgery, stereotactic radiation therapy, and whole-brain radiation therapy are currently considered the gold standard treatments. Meanwhile, new targeted therapies based on subtype have recently been developed. Some drugs can exceed the blood–brain barrier and enter the central nervous system. New technology for early detection and personalized medicine for metastasis are warranted. In this review, we summarize the historical overview of treatment with a focus on local treatment, the latest drug treatment strategies, and future perspectives using novel therapeutic agents for breast cancer patients with brain metastasis, including ongoing clinical trials.

show abstract

Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer

Woo,

Han,

Suh

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose The tumor immune microenvironment can change after neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC). We aimed to investigate the effects of NAC on PD-L1 (SP142) status and its clinical significance in TNBC. Methods Paired samples of biopsy and resection specimens were collected from 182 patients with TNBC before and after NAC. PD-L1 (SP142) expression in immune cells in pre- and post-NAC breast cancer samples and the changes between them were analyzed, along with their relationships with the clinicopathological features and clinical outcomes of the patients. Results Of the 182 patients, 61 (33.5%) achieved pathologic complete response (pCR) after NAC. PD-L1 (SP142) positivity, defined as immune cell staining in ≥ 1% of tumor area, was a predictor for pCR. PD-L1-positive immune cells significantly increased after NAC (2.8% to 5.2% on average) in 109 patients with measurable residual disease. Alteration of PD-L1 status was observed in 24 (22.0%) of the 109 patients with measurable residual tumors after NAC, and all PD-L1 status-converted patients, except one, revealed negative-to-positive conversion. Regarding chemotherapeutic agents, the use of platinum agents was associated with a significant increase in PD-L1-positive immune cells after NAC. In survival analyses, a positive PD-L1 status after NAC and increase of PD-L1-positive immune cells after NAC were associated with better recurrence-free survival of the patients. Conclusion PD-L1 (SP142) status changes after NAC, mostly as a positive conversion. As PD-L1 (SP142) status can convey prognostic and predictive information, it needs to be tested before and after NAC.

show abstract

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer

Cited by 29 publications

References 27 publications

Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives

Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer

Contact Info

Product

Resources

About